These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3439807)

  • 1. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.
    O'Keefe JP; Venezio FR; DiVincenzo CA; Shatzer KL
    Antimicrob Agents Chemother; 1987 Dec; 31(12):2002-4. PubMed ID: 3439807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.
    Cuchural GJ; Tally FP; Jacobus NV; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C
    Antimicrob Agents Chemother; 1990 Mar; 34(3):479-80. PubMed ID: 2334161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
    Downes J; Andrew JH
    Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newer beta-lactam agents and the Bacteroides fragilis group.
    Cuchural GJ
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
    Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
    Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
    Bourgault AM; Lamothe F
    J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
    Goldstein EJ; Citron DM
    J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
    Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
    J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1546-50. PubMed ID: 2221864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
    Appelbaum PC; Spangler SK; Jacobs MR
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of the Bacteroides fragilis group in community hospitals.
    File TM; Thomson RB; Tan JS; Salstrom SJ; Jacobs GA; Johnson L; Tan L
    Diagn Microbiol Infect Dis; 1986 Nov; 5(4):317-22. PubMed ID: 3465493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
    Aldridge KE; Ashcraft D; O'Brien M; Sanders CV
    Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
    Betriu C; Cabronero C; Gomez M; Picazo JJ
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan.
    Watanabe K; Ueno K; Kato N; Muto Y; Bandoh K; Tanaka Y; Jotwani R; Goto M; Shimada K; Shimizu K
    Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1069-73. PubMed ID: 1295761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of Bacteroides fragilis susceptibility patterns in France.
    Breuil J; Burnat C; Patey O; Dublanchet A
    J Antimicrob Chemother; 1989 Jul; 24(1):69-75. PubMed ID: 2777729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR; Spangler SK; Appelbaum PC
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.
    Teng LJ; Ho SW; Chang SC; Luh KT; Hsieh WC
    J Formos Med Assoc; 1991 Aug; 90(8):796-9. PubMed ID: 1683376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.
    Appleman MD; Heseltine PN; Cherubin CE
    Rev Infect Dis; 1991; 13(1):12-8. PubMed ID: 2017610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.